Unicycive Therapeutics, Inc. (UNCY) Earnings History
Annual and quarterly earnings data from 2018 to 2024
Loading earnings history...
UNCY EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
UNCY Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | 100.0% | -3077.6% | -4525.0% |
| 2022 | 100.0% | -1898.2% | -1898.8% |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export UNCY earnings history in CSV or JSON format
Free sign-in required to download data
Unicycive Therapeutics, Inc. (UNCY) Earnings Overview
As of May 7, 2026, Unicycive Therapeutics, Inc. (UNCY) reported trailing twelve-month net income of -$33M, reflecting -337.5% year-over-year growth. The company earned $-1.85 per diluted share over the past four quarters.
Looking at the long-term picture, UNCY's historical earnings data spans multiple years. The company achieved its highest annual net income of -$1M in fiscal 2018.
Unicycive Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ARWR ($202M net income, -0.2% margin), CYCN (-$4M net income, -170.1% margin), RMTI (-$6M net income, -0.5% margin), UNCY has comparable earnings metrics. Compare UNCY vs ARWR →
UNCY Earnings vs Peers
Earnings metrics vs comparable public companies
UNCY Historical Earnings Data (2018–2024)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$37M | -20.2% | -$32M | $-5.60 | - | - |
| 2023 | -$31M | -69.1% | -$21M | $-1.28 | -4525.0% | -3077.6% |
| 2022 | -$18M | -80.3% | -$18M | $-1.20 | -1898.8% | -1898.2% |
| 2021 | -$10M | -299.4% | -$9M | $-8.60 | - | - |
| 2020 | -$3M | -8.9% | -$2M | $-0.16 | - | - |
| 2019 | -$2M | -105.7% | -$2M | $-0.27 | - | - |
| 2018 | -$1M | - | $-952,000 | $-0.14 | - | - |
See UNCY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs UNCY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare UNCY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonUNCY — Frequently Asked Questions
Quick answers to the most common questions about buying UNCY stock.
Is UNCY growing earnings?
UNCY EPS fell to $-1.85, with earnings declining -337.5%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-33M.
What are UNCY's profit margins?
Unicycive Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are UNCY's earnings?
UNCY earnings data spans 2018-2024. The declining earnings trend is -337.5% YoY. Historical data enables comparison across business cycles.